Literature DB >> 22397940

Phosphorylation status of matrix metalloproteinase 2 in myocardial ischaemia-reperfusion injury.

Meltem Sariahmetoglu1, Monika Skrzypiec-Spring, Nermeen Youssef, Anna Laura B Jacob-Ferreira, Jolanta Sawicka, Charles Holmes, Grzegorz Sawicki, Richard Schulz.   

Abstract

OBJECTIVE: To investigate whether alterations in the phosphorylation status of matrix metalloproteinase 2 (MMP-2) in the heart may be protective in the setting of ischaemia-reperfusion (IR) injury.
DESIGN: In-vitro heart function and biochemical research study.
SETTING: University basic science laboratory.
INTERVENTIONS: Male Sprague-Dawley rats, weighing 250-350 g. Isolated rat hearts were perfused at constant pressure either aerobically for 75 min or subjected to 20 min of global, no-flow ischaemia followed by 30 min of reperfusion. MAIN OUTCOME MEASURES: Heart mechanical function, MMP-2 activity and troponin I levels.
RESULTS: The serine/threonine phosphatase inhibitor okadaic acid (OA) improved the recovery of mechanical function compared with control IR hearts and prevented the loss of troponin I. OA significantly reduced protein phosphatase 2A, but not protein phosphatase 1, activity in perfused hearts. IR stimulated the activation and release of MMP-2 into the coronary effluent in the first 2 min of reperfusion. This was accompanied by a decrease in the remaining activity and protein level of MMP-2 in heart tissue determined at the end of the reperfusion. OA did not alter the IR-stimulated release of MMP-2 into the coronary effluent, but reduced the decrease in MMP-2 in reperfused hearts. The immunoprecipitation of heart homogenates using anti-phosphoserine antibody showed that MMP-2 is phosphorylated. The dephosphorylation of MMP-2 by alkaline phosphatase treatment of homogenates prepared from IR hearts treated with OA significantly increased MMP-2 activity.
CONCLUSIONS: These results suggest that the phosphorylation status of MMP-2 is important in its contribution to myocardial IR injury.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22397940     DOI: 10.1136/heartjnl-2011-301250

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  8 in total

Review 1.  Myocardial matrix metalloproteinase-2: inside out and upside down.

Authors:  Ashley DeCoux; Merry L Lindsey; Francisco Villarreal; Ricardo A Garcia; Richard Schulz
Journal:  J Mol Cell Cardiol       Date:  2014-09-28       Impact factor: 5.000

2.  Epigenetic Regulation of the N-Terminal Truncated Isoform of Matrix Metalloproteinase-2 (NTT-MMP-2) and Its Presence in Renal and Cardiac Diseases.

Authors:  Juliana de Oliveira Cruz; Alessandra O Silva; Jessyca M Ribeiro; Marcelo R Luizon; Carla S Ceron
Journal:  Front Genet       Date:  2021-02-25       Impact factor: 4.599

3.  Phosphorylation status of 72 kDa MMP-2 determines its structure and activity in response to peroxynitrite.

Authors:  Anna Laura Jacob-Ferreira; Marcia Yuri Kondo; Pravas Kumar Baral; Michael N G James; Andrew Holt; Xiaohu Fan; Richard Schulz
Journal:  PLoS One       Date:  2013-08-27       Impact factor: 3.240

Review 4.  Intracellular regulation of matrix metalloproteinase-2 activity: new strategies in treatment and protection of heart subjected to oxidative stress.

Authors:  Grzegorz Sawicki
Journal:  Scientifica (Cairo)       Date:  2013-12-24

5.  Tissue Expression of Atrial and Ventricular Myosin Light Chains in the Mechanism of Adaptation to Oxidative Stress.

Authors:  Marta Banaszkiewicz; Anna Krzywonos-Zawadzka; Agnieszka Olejnik; Iwona Bil-Lula
Journal:  Int J Mol Sci       Date:  2020-11-09       Impact factor: 5.923

6.  Expression of atrial‑fetal light chains in cultured human cardiomyocytes after chemical ischemia‑reperfusion injury.

Authors:  Marta Banaszkiewicz; Agnieszka Olejnik; Anna Krzywonos-Zawadzka; Kornela Hałucha; Iwona Bil-Lula
Journal:  Mol Med Rep       Date:  2021-09-07       Impact factor: 2.952

7.  The Protective Effect of Simvastatin on the Systolic Function of the Heart in the Model of Acute Ischemia and Reperfusion Is Due to Inhibition of the RhoA Pathway and Independent of Reduction of MMP-2 Activity.

Authors:  Monika Skrzypiec-Spring; Agnieszka Sapa-Wojciechowska; Alina Rak-Pasikowska; Maciej Kaczorowski; Iwona Bil-Lula; Agnieszka Hałoń; Adam Szeląg
Journal:  Biomolecules       Date:  2022-09-13

8.  Matrix Metalloproteinase-2 Inhibition in Acute Ischemia-Reperfusion Heart Injury-Cardioprotective Properties of Carvedilol.

Authors:  Monika Skrzypiec-Spring; Joanna Urbaniak; Agnieszka Sapa-Wojciechowska; Jadwiga Pietkiewicz; Alina Orda; Bożena Karolko; Regina Danielewicz; Iwona Bil-Lula; Mieczysław Woźniak; Richard Schulz; Adam Szeląg
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.